Miami Fort Lauderdale, FL, June 20, 2026 —

Miami-Fort Lauderdale Study Compares GLP-1 Medication Effectiveness

Researchers in the Miami-Fort Lauderdale area are conducting a new meta-study to compare the effectiveness of several GLP-1 medications. The study focuses on tirzepatide, marketed as Zepbound and Mounjaro; semaglutide, known as Wegovy and Ozempic; and liraglutide, sold under the brand names Saxenda and Victoza.

The meta-study aims to provide a comparative analysis of these drugs within the GLP-1 class. Specific details regarding the study’s methodology, participant numbers, or projected completion dates were not provided in the summary.

GLP-1 medications have gained attention for their role in managing conditions such as type 2 diabetes and obesity. This research intends to shed further light on their relative efficacy.

Story summarized from the original created by Alix Martichoux on thehill.com, see more information here.

Media gallery